CTIS2023-506307-26-00招募中1 期
A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients with CD19-Positive Relapsed/ Refractory (r/r) B cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B cell Non-Hodgkin Lymphoma (B NHL) - AUTO1-PY1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Male or female participants < 18 years old at screening, Patients with =6 kg body weight at screening, Willing and able to give written, informed consent to the current study (participant and/or parent or legal guardian)., Agreement to have a pregnancy test and use adequate contraception (if applicable)., Patients with diagnosis of: a. B ALL: r/r CD19-positive B ALL defined as one of the following: i. Primary refractory disease including: a) National Cancer Institute (NCI) high risk or Children’s Oncology Group (COG) high risk patients with MRD = 0.1% EOI (end of induction) or > 0.01% at EOC (end of consolidation) as assessed by flow cytometry. b) COG intermediate risk cytogenetics with MRD = 1% EOI as assessed by flow cytometry. c) COG good risk cytogenetics with = 5% disease EOI as assessed. d) Down syndrome with MRD = 0.01% EOC as assessed by flow cytometry. e) High risk infant ALL (MRD-positive disease as assessed by flow cytometry post induction and blinatumomab) ii. COG very high risk (VHR) first relapse if first remission = 18 months. iii. Relapsed or refractory disease after two or more lines of systemic therapy. iv. Relapsed or refractory disease after allogeneic transplant provided AUTO1 infusion occurs = 3 months after stem cell transplant. v. Any of the above with Philadelphia chromosome positive disease (Ph+ ALL) where patient is intolerant to or has failed at least one tyrosine kinase inhibitor (TKI) or if TKI therapy is contraindicated. OR b. B NHL: r/r CD19-positive aggressive mature B NHL defined as one of the following: i. Relapsed after one or more prior therapies (can include allogeneic and autologous hematopoietic stem cell transplant) ii. Primary refractory (have not achieved a CR or PR after the first line of therapy) with measurable disease by radiological criteria at screening including the following B NHL subtypes: i. Diffuse large B cell lymphoma (DLBCL) ii. Burkitt’s lymphoma (BL) iii. Primary mediastinal large B cell lymphoma (PMBCL) iv. High-grade B cell lymphoma not otherwise specified (NOS)., Karnofsky (age = 10 years) or Lansky (age < 10 year) performance status score = 50%., In patients with B ALL, local documentation of CD19 expression on leukemic blasts in the BM, peripheral blood or cerebrospinal fluid (CSF), or biopsy, done no more than 30 days prior to consent. In patients treated with blinatumomab, testing should be undertaken after blinatumomab therapy has been stopped. In patients with mature B NHL, CD19 expression must be confirmed in a biopsy after any CD19 targeted therapies.
排除标准
- •Chronic myelogenous leukemia lymphoid in blast crisis., History or presence of clinically relevant CNS pathology, Presence of CNS 3 disease or CNS 2 disease with neurological changes at screening, Presence of active or uncontrolled fungal, bacterial, viral, or other infection requiring systemic antimicrobials for management., History or presence of active or latent Hepatitis B virus or active Hepatitis C virus., History of human immunodeficiency virus (HIV), human T cell lymphotropic virus (HTLV)-1, HTLV-2, or syphilis positive test., Prior CD19 targeted therapy other than blinatumomab., Patients who have experienced = Grade 3 neurotoxicity following blinatumomab.
研究者
相似试验
已完成
不适用
A study to evaluate the Safety and Efficacy of Nivolumab in Combination with Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerKCT0004186Yonsei University Health System, Severance Hospital62
招募中
不适用
An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Efficacy of Paclitaxel in Combination with Pembrolizumab and Olaparib as a Second Line Treatment in Immune Checkpoint Inhibitor-experienced Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerNeoplasmsKCT0006101Yonsei University Health System, Severance Hospital77
已完成
不适用
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a second-line therapy for recurrent / progressive gastric cancer with INCB054828 and paclitaxel a study to evaluate the safety and efficacy of combination therapy.KCT0003844Yonsei University Health System, Severance Hospital42
已完成
不适用
Phase Ib/II Study of M7824 and Paclitaxel Combination in Recurrent/Metastatic Gastric Cancer as a Second-line TreatmentKCT0006078Yonsei University Health System, Severance Hospital49
招募中
1 期
Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell LymphomaCTIS2022-500687-35-00Beigene Ltd.130